Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Objective: This network meta‐analysis evaluates the efficacy and safety of tirzepatide compared to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and other weight loss drugs in the treatment of overweight and obesity. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched for randomized controlled trials on tirzepatide, GLP‐1 RA, and weight loss drugs approved by the US Food and Drug Administration. A network meta‐analysis was performed, drawing direct and indirect comparisons between treatment groups. Network diagrams and surface under the cumulative ranking curve analysis were performed for primary (≥5%, ≥10%, ≥15%, absolute weight loss) and secondary outcomes and adverse effects. Results: Thirty‐one randomized controlled trials, involving more than 35,000 patients, were included in this study. Tirzepatide 15 mg ranked in the top three across weight‐related parameters, glycemic profile (glycated hemoglobin), lipid parameters (total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides), and blood pressure. Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42–16.34). As compared to placebo, tirzepatide and GLP‐1 RA across all doses had significant increases in gastrointestinal adverse effects. Conclusions: The superiority of tirzepatide and GLP‐1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“When continuous variables in means and standard deviations were not provided, they were derived from their respective medians and interquartile ranges using formulas devised by Wan et al. [26].”
MethodOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“3.0% to 8.6%, with significant adverse side effects [66, 70, 71].”
BackgroundInfluentialSalanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“To analyze the validity of the indirect comparisons, consistency was measured using local nodes splitting and Wald testing [33 – 35].”
MethodDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 1×
“The use of medications such as liraglutide, semaglutide, and tirze-patide is aligned with the 2022 guidance of the American Diabetes Association and the European Association for the Study of Diabetes, which has made weight loss a priority in patients with T2DM [78].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 2×
“Data from the Diabetes Remission Clinical Trial (DiRECT) reported that 86% of participants achieved T2DM remission when they lost 15 kg, and 73% remission was achieved with more than 10 kg of weight loss [10].”
BackgroundMethodA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“Semaglutide and liraglutide have been shown to reduce liver fat and improve liver biomarkers in patients with nonalcoholic steatohepatitis [91, 92].”
BackgroundBray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020786 · Cited by 1,441
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 3×
“3.0% to 8.6%, with significant adverse side effects [66, 70, 71].”
BackgroundInfluentialRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995 · cited 1×
“…weight loss medications, GLP-1 receptor agonists showed significant improvements in multiple aspects of metabolic syndrome, with semaglutide having greater efficacy than liraglutide in weight-related measures and glycemia (HbA1c), which is supported by other studies, including the STEP 8 RCT [77].”
ResultMaintenance of Lost Weight and Long-Term Management of Obesity
Hall, K. D., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.012 · Cited by 876 · cited 1×
“Treatment of obesity requires effective weight lowering and maintenance [12].”
BackgroundKhera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Bariatric Surgery and Long-term Durability of Weight Loss
Maciejewski, M. L., Arterburn, D. E., Van Scoyoc, L., Smith, V. A., Yancy, W. S., Weidenbacher, H. J., Livingston, E. H., & Olsen, M. K. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.2317 · Cited by 720
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581 · cited 1×
“The hope is that substantial weight loss can disrupt the disease of T2DM [ 79].”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Leitner, D. R., Frühbeck, G., Yumuk, V., Schindler, K., Micic, D., Woodward, E., & Toplak, H. (2017) · Obesity Facts · doi:10.1159/000480525 · Cited by 431 · cited 1×
“Overweight and obesity account for 44% of T2DM cases, with CVD accounting for 70% of deaths in patients with obesity [85, 86].”
BackgroundGorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · cited 1×
“This can be managed by initiating at a lower dose, followed by slow dose escalation and using antiemetics when required [20, 83].”
BackgroundKadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306 · cited 1×
“GLP-1 receptor agonists and tirzepatide have displayed renal protective effects in diabetic kidney disease [94, 95].”
BackgroundGLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Halawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224
A review of current guidelines for the treatment of obesity
(2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89292 · Cited by 207
Neeland, I. J., Marso, S. P., Ayers, C. R., Lewis, B., Oslica, R., Francis, W., Rodder, S., Pandey, A., & Joshi, P. H. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00179-0 · Cited by 202
Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200
Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Maselli, D., Atieh, J., Clark, M. M., Eckert, D., Taylor, A., Carlson, P., Burton, D. D., Busciglio, I., Harmsen, W. S., Vella, A., et al. (2022) · Obesity · doi:10.1002/oby.23481 · Cited by 136
Singh, A. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1698291 · Cited by 130
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity · doi:10.1002/oby.23673 · Cited by 124
Describing the Weight‐Reduced State: Physiology, Behavior, and Interventions
Aronne, L. J., Hall, K. D., M. Jakicic, J., Leibel, R. L., Lowe, M. R., Rosenbaum, M., & Klein, S. (2021) · Obesity · doi:10.1002/oby.23086 · Cited by 113 · cited 1×
“As a complex disease involving multiple factors and systems, it is important to consider pharmacotherapy to enhance weight loss management and improve sustained weight loss [13].”
BackgroundTan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01321-5 · Cited by 83 · cited 2×
“Tirzepatide has generated significant interest due to its dual GLP-1 and GIP receptor agonist properties, targeting multiple aspects of cardiometabolic outcomes and producing superior weight loss compared to older weight loss drugs [18, 22].”
BackgroundSelf-citationde Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59 · cited 3×
“Fortunately, GI adverse effects are usually transient and improve with time, occurring mainly in the initiation and dose escalation periods [20].”
BackgroundJeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39 · cited 1×
“Other studies have also reported similar results in which tirzepatide improved metabolic conditions of patients with mild to moderate adverse effects [76].”
ResultRoborel de Climens, A., Pain, E., Boss, A., & Shaunik, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00843-9 · Cited by 38 · cited 1×
“Although these adverse effects may not be severe, they remain a cause of concern because GI side effects are common causes of discontinuation of T2DM medications [16, 82].”
Backgroundle Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15148 · Cited by 36 · cited 1×
“This can be explained by tirzepatide ’ s additional effect on GIP receptors in addition to being a GLP-1 receptor agonist [80].”
BackgroundThere is no magic bullet for obesity
Lingvay, I., Sumithran, P., le Roux, C. W., & Cohen, R. V. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00191-2 · Cited by 16
Research works printed but not linked: 35
- 10.1016/j.metabol.2018.09.005 · DOI · Paper page
- 10.1093/ajcn/72.3.694 · DOI · Paper page
- 10.1136/bmjgh‐2022‐009773 · DOI · Paper page
- World Obesity, 2023, World Obesity Atlas 2023
- Lobstein T, World Obesity Atlas 2022
- 10.1016/j.eprac.2022.10.006 · DOI
- 10.1038/s41430‐020‐0610‐y · DOI
- 10.1046/j.1365‐2125.2001.01294.x · DOI
- 10.1900/RDS.2014.11.202 · doi:10.1900/rds.2014.11.202
- 10.7570/jomes22012 · DOI
- 10.1371/journal.pone.0285197 · DOI · Paper page
- 10.1016/S0140‐6736(03)15268‐3 · DOI · Paper page
- 10.1002/jrsm.1058 · DOI · Paper page
- 10.1002/sim.6236 · DOI · Paper page
- 10.1002/jrsm.1143 · DOI
- 10.1002/sim.8158 · DOI · Paper page
- 10.18549/PharmPract.2017.01.943 · DOI · Paper page
- 10.3945/ajcn.111.024927 · DOI · Paper page
- 10.1016/S0140‐6736(10)60888‐4 · DOI · Paper page
- 10.1038/oby.2009.155 · DOI · Paper page
- 10.1016/S0140‐6736(18)31773‐2 · DOI · Paper page
- 10.2337/dc13‐0354 · DOI
- 10.1001/jama.2021.3224 · DOI · Paper page
- 10.1016/S0140‐6736(23)01200‐X · DOI · Paper page
- 10.2165/00002018‐200831010‐00005 · DOI · Paper page
- 10.3390/ph14100991 · DOI · Paper page
- 10.1161/CIRCRESAHA.116.307591 · DOI · Paper page
- 10.3389/fphar.2022.998816 · DOI
- 10.3389/fcvm.2021.768119 · DOI · Paper page
- 10.1016/S0140‐6736(15)00803‐X · DOI · Paper page
- 10.1016/S2213‐8587(22)00070‐5 · DOI · Paper page
- 10.23876/j.krcp.22.001 · DOI
- 10.1111/j.1755‐5949.2010.00172.x · DOI · Paper page
- 10.5414/CP202135 · DOI
- 10.1111/j.1463‐1326.2010.01242.x · DOI · Paper page
Cited by
Global burden of cardiovascular diseases: projections from 2025 to 2050
Chong, B., Jayabaskaran, J., Jauhari, S. M., Chan, S. P., Goh, R., Kueh, M. T. W., Li, H., Chin, Y. H., Kong, G., Anand, V. V., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae281 · Cited by 793
Self-citationObesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Metadata
- Authors
- Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., Grandhi, G. R., Dimitriadis, G. K., Foo, R., Chew, N. W. S., Le Roux, C. W., Mamas, M. A., & Chan, M. Y.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2024-02-27
- Volume
- 32
- Issue
- 5
- Pages
- 840-856
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W4392772523
- Cited by
- 71
- References
- 59
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.